NewsCore
    santéDataInformationVeille

    Dupixent: the asset that worries Sanofi

    Dupixent, the pillar of Sanofi's sales, is expected to lose key patents from 2031, which raises concerns despite the group's diversification efforts.

    16 February 20263 min read
    Dupixent: the asset that worries Sanofi

    Sanofi, France's pharmaceutical flagship and one of the world leaders in the sector, closed 2025 with solid growth. According to its annual results press release published on 29 January 2026, sales rose by 9.9% at constant exchange rates and business earnings per share by 15%. But this performance hides a major strategic vulnerability: dependence on Dupixent, an antibody against type 2 inflammatory diseases (atopic dermatitis, asthma, COPD).

    A blockbuster that carries the group

    According to Pharmaceutical Technology, Sanofi generated €43.6 billion in net sales in 2025. Dupixent, developed and marketed in partnership with Regeneron, accounted for €15.7 billion of this, up 25.2% at constant exchange rates, after €13 billion in 2024. The drug therefore represents more than a third of the group's sales. Momentum even accelerated at the end of the year: in the fourth quarter, its sales grew by 32.2% to €4.2 billion, according to Sanofi's press release.

    This growth rests on the continued expansion of clinical indications, which widens the treatable patient population year after year. This is precisely what makes the question of life after Dupixent so sensitive: the bigger the product grows, the deeper the hole to be filled.

    The 2031 horizon

    This positive momentum comes with a structural uncertainty. As Boursorama reports, Dupixent is expected to lose key patents from 2031, which will open the way for biosimilars and threaten both its commercial exclusivity and its high margins. For 2026, Sanofi is targeting high single-digit sales growth, still driven to a large extent by this same product. Investors and financial analysts point to this concentration as the stock's main source of vulnerability.

    The exact timetable remains debated: the group intends to defend Dupixent's intellectual property beyond 2031 through secondary patents (formulations, new indications), the outcome of which will depend on future proceedings and litigation.

    The diversification strategy

    Sanofi is trying to mitigate this risk on three fronts: launching new products (in the fourth quarter of 2025, sales of new pharmaceutical launches grew by 49.4% according to the group's press release), targeted acquisitions to fill the portfolio, and extending Dupixent's indications. Several late-stage clinical trial disappointments in 2025 have, however, dented market confidence in the pipeline's ability to take over in time.

    Dependence on a single blockbuster illustrates a classic fragility of the pharmaceutical value chain and underlines the need to diversify the portfolio to ensure the group's lasting resilience.

    What is at stake beyond Sanofi

    The loss of exclusivity of a product this size reshuffles the cards across an entire market. Biosimilar manufacturers prepare their dossiers years in advance, payers (public health insurance, private insurers) anticipate price cuts, and competitors positioned on the same inflammatory indications see a window of opportunity. For biologics manufacturing subcontractors and Sanofi's partners, Dupixent's trajectory determines volumes and investments over the medium term.

    What monitoring teams should watch

    1. Patent litigation and filings around Dupixent in the United States and Europe, which will set the actual arrival date of biosimilars.
    2. Clinical trials of dupilumab biosimilars and announcements by their developers, an early signal of competitive pressure, to be built into competitive intelligence.
    3. Phase 3 results from Sanofi's immunology pipeline, and the group's external growth transactions.
    4. Decisions by health authorities on new indications and on antibody pricing, to be tracked through pharmaceutical sector monitoring.
    5. Quarterly reports and Dupixent's share of sales, a simple indicator of the group's dependence, at the heart of any economic monitoring of the sector.

    Sources

    Go deeper

    All reports

    Three NewsCore reports that build on this article.